We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Management of Prostate Cancer in Central China

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01614548
First Posted: June 8, 2012
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
The First Affiliated Hospital of Zhengzhou University
the cancer hospital of Zhengzhou University
Third Affiliated Hospital of Zhengzhou University
People's Hospital of Zhengzhou University
Xinyang Central Hospital
Zhoukou Central Hospital
Center hospital of Nanyang
Center hospital of Shangqiu
Center hospital of Zhumadian
Anyang Regional Hospital
Luoyang Central Hospital
First People's Hospital of Kaifeng
Information provided by (Responsible Party):
Liu Bingqian, Zhengzhou University
  Purpose

Some recent reports indicate that incidence of prostate cancer is increasing rapidly in China. However, no large-scale survey of prostate cancer has been done in central China, few data are available regarding its management. The investigators aimed to analyze the management of prostate cancer and compare the outcome of patients with such a survey.

The investigators collected data of patients diagnosed with prostate cancer from the 2003 and 2008 in central China. Data were disaggregated by rural and urban hukou. The survival rate of patients was analyzed using Kaplan-Meier method. Prognostic factors were analyzed using the log-rank test and Cox proportional hazards model.


Condition
Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Comparisons of Management and Outcome of Prostate Cancer in Central China Between 2003 and 2008: A Multi-institutional Report

Resource links provided by NLM:


Further study details as provided by Liu Bingqian, Zhengzhou University:

Primary Outcome Measures:
  • overall survival [ Time Frame: 3 years ]
    overall survival that was defined as the interval from the date of diagnosis to the Medicare date of death


Enrollment: 789
Study Start Date: January 2003
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
all patients
We selected 9 cities (Zhengzhou, Luoyang, Kaifeng, Anyang, Xinyang, Zhoukou, Shangqiu, Nanyang, Zhumadian) by probability proportional to size sampling from geographical regions in central China. All cases with complete follow-up data of histological-proven prostate cancer treated in 2003 and 2008 at 14 department of urology in the 9 cities were retrospectively collected. Only patients with newly diagnosed prostate cancer were included in the study. Those with a history of prostate cancer who were treated for another disease were excluded from study.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
all inpatients with prostate cancer in 14 hospitals
Criteria

Inclusion Criteria:

  • patients with newly diagnosed prostate cancer were included in the study. Exclusion Criteria:
  • Those with a history of prostate cancer who were treated for another disease were excluded from study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01614548


Locations
China, Henan
the first affiliated hospital of Zhengzhou University
Zhengzhou, Henan, China, 450052
Sponsors and Collaborators
Zhengzhou University
The First Affiliated Hospital of Zhengzhou University
the cancer hospital of Zhengzhou University
Third Affiliated Hospital of Zhengzhou University
People's Hospital of Zhengzhou University
Xinyang Central Hospital
Zhoukou Central Hospital
Center hospital of Nanyang
Center hospital of Shangqiu
Center hospital of Zhumadian
Anyang Regional Hospital
Luoyang Central Hospital
First People's Hospital of Kaifeng
Investigators
Principal Investigator: Liu Bingqian, Ph.D MD The First Affiliated Hospital of Zhengzhou University
  More Information

Responsible Party: Liu Bingqian, Principal Investigator, Zhengzhou University
ClinicalTrials.gov Identifier: NCT01614548     History of Changes
Other Study ID Numbers: ZZU2012
First Submitted: June 2, 2012
First Posted: June 8, 2012
Last Update Posted: October 12, 2017
Last Verified: June 2012

Keywords provided by Liu Bingqian, Zhengzhou University:
Prostatic Neoplasms
Prostate Cancer
Disease Management
Rural
Urban

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases